Table 6.
Univariable Cox Regression for the secondary endpoints of sustained VT and recurrent myocarditis
| Sustained VT Univariable analyses |
Recurrent myocarditis Univariable analyses |
|||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Clinical characteristics | ||||
| Age [years] | 1.00 (0.98–1.03) | 0.742 | 0.94 (0.91–0.98) | 0.002 |
| Gender [male] | 0.80 (0.40–1.59) | 0.523 | 1.31 (0.46–3.78) | 0.614 |
| Troponin T peaka [ng/l] | 1.00 (0.99–1.00) | 0.266 | 1.00 (1.00–1.00) | 0.301 |
| NT-proBNPa [log pg/ml] | 1.27 (0.54–2.99) | 0.584 | 0.70 (0.20–2.46) | 0.576 |
| CMR LGE | ||||
| LV LGE present | 2.47 (1.18–4.54) | 0.012 | 2.30 (0.66–8.08) | 0.194 |
| LV LGE involves insertion points | 1.50 (0.67–3.34) | 0.320 | 0.70 (0.16–3.11) | 0.641 |
| LV LGE extent FWHM [g] | 1.07 (1.05–1.10) | < 0.001 | 1.03 (0.97–1.09) | 0.393 |
| RV LGE presenta | 2.48 (0.96–6.42) | 0.061 | 1.21 (0.32–4.58) | 0.783 |
| CMR ejection fraction | ||||
| LV EF [%] | 0.96 (0.94–0.98) | < 0.001 | 1.07 (1.02–1.13) | 0.009 |
| RV EF [%] | 0.95 (0.93–0.97) | < 0.001 | 1.04 (0.99–1.09) | 0.106 |
| CMR feature tracking | ||||
| LV GLS [%] | 1.13 (1.05–1.21) | 0.002 | 0.82 (0.71–0.95) | 0.009 |
| LV GCS [%] | 1.13 (1.06–1.21) | < 0.001 | 0.86 (0.76–0.97) | 0.014 |
| LV GRS [%] | 0.93 (0.90–0.97) | < 0.001 | 1.06 (1.01–1.11) | 0.017 |
| RV GLS [%] | 1.02 (0.96–1.08) | 0.509 | 0.95 (0.86–1.04) | 0.258 |
CI: confidence intervals; EF: ejection fraction; FWHM: full width half max; GCS/GLS/GRS: global circumferential/longitudinal/radial strain; HR: Hazard ratio; LGE: late gadolinium enhancement; LV: left ventricle; NT-proBNP: N-terminal pro-hormone brain natriuretic peptide; RV: right ventricle; VT: ventricular tachycardia
aVariables with > 20% missing values. Troponin was available in 338 (51.3%) patients. NT-proBNP was available in 159 (24.1%) of patients. RV LGE was not assessable in 270 (41%) of patients